India, Nov. 10 -- Healthcare stocks moved higher following clinical, financial and corporate updates. PepGen reported positive Phase 2 data for its muscular dystrophy candidate, Zura Bio discontinued a setback-hit clinical program, NeOnc's CEO made additional open-market share purchases, and Senseonics raised its full-year revenue outlook after strong third-quarter growth.
Read on.....
PepGen Inc. (PEPG)
Shares surged 114.18% after positive Phase 2 FREEDOM2-DM1 results showed 46.5% mean splicing correction with PGN-EDODM1 at 10 mg/kg, alongside improvements in muscle strength and mobility. All participants in the 12.5 mg/kg cohort have enrolled and received up to three doses, with results expected in the first half of 2027. Third-quarter...